Who
Michael E. Faerm
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, AtaiBeckley; Chief Financial Officer, Viracta Therapeutics; Sr VP & Chief Business Officer, Innoviva.
In numbers
- Trades disclosed
- 18
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 23 Jul 2015
- Last trade
- 11 Sep 2026
- Last filed
- 11 Sep 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,275,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —285,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,275,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —285,000 | filing |
| 11 Mar 2026filed 13 Mar 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,275,000 at $0.00 | filing |
| 11 Mar 2026filed 13 Mar 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code A | —285,000 at $0.00 | filing |
| 11 Mar 2026filed 13 Mar 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,275,000 at $0.00 | filing |
| 11 Mar 2026filed 13 Mar 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code A | —285,000 at $0.00 | filing |
| 14 May 2024filed 16 May 2024 | Viracta Therapeuticsoption or derivative | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 20 Nov 2017filed 22 Nov 2017 | INVA InnovivaPharmaceuticals | SEC FORM 4 Code F | $59K4,470 at $13.17 | filing |
| 20 Aug 2017filed 22 Aug 2017 | INVA InnovivaPharmaceuticals | SEC FORM 4 Code F | $39K3,179 at $12.28 | filing |
| 20 May 2017filed 23 May 2017 | INVA InnovivaPharmaceuticals | SEC FORM 4 Code F | $38K3,176 at $11.86 | filing |
| 20 Feb 2017filed 22 Feb 2017 | INVA InnovivaPharmaceuticals | SEC FORM 4 Code F | $71K5,860 at $12.04 | filing |
| 17 Jan 2017filed 19 Jan 2017 | INVA InnovivaPharmaceuticals | SEC FORM 4 Code A | —133,398 at $0.00 | filing |
| 20 Nov 2016filed 22 Nov 2016 | INVA InnovivaPharmaceuticals | SEC FORM 4 Code F | $32K2,893 at $10.91 | filing |
| 20 Aug 2016filed 23 Aug 2016 | INVA InnovivaPharmaceuticals | SEC FORM 4 Code F | $113K9,544 at $11.79 | filing |
| 14 Jan 2016filed 19 Jan 2016 | INVA InnovivaPharmaceuticals | SEC FORM 4 Code A | —67,126 at $0.00 | filing |
| 23 Jul 2015filed 27 Jul 2015 | INVA InnovivaPharmaceuticals | SEC FORM 4 Code A | —105,288 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.